Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Capital Expenditures (2023 - 2025)

Historic Capital Expenditures for bioAffinity Technologies (BIAF) over the last 3 years, with Q3 2025 value amounting to -$3646.0.

  • bioAffinity Technologies' Capital Expenditures fell 13874.6% to -$3646.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $60568.0, marking a year-over-year decrease of 772.7%. This contributed to the annual value of $79083.0 for FY2024, which is 24531.05% up from last year.
  • Per bioAffinity Technologies' latest filing, its Capital Expenditures stood at -$3646.0 for Q3 2025, which was down 13874.6% from $13427.0 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Capital Expenditures ranged from a high of $50786.0 in Q1 2025 and a low of -$13442.0 during Q4 2023
  • Moreover, its 3-year median value for Capital Expenditures was $9410.0 (2024), whereas its average is $14777.5.
  • In the last 5 years, bioAffinity Technologies' Capital Expenditures surged by 546804.73% in 2024 and then crashed by 13874.6% in 2025.
  • Over the past 3 years, bioAffinity Technologies' Capital Expenditures (Quarter) stood at -$13442.0 in 2023, then skyrocketed by 100.01% to $1.0 in 2024, then tumbled by 364700.0% to -$3646.0 in 2025.
  • Its last three reported values are -$3646.0 in Q3 2025, $13427.0 for Q2 2025, and $50786.0 during Q1 2025.